Meeting Overview - The company will hold a shareholder meeting on September 17, 2025, at 14:30 in Kunming, Yunnan Province [1] - The meeting will utilize a combination of on-site and online voting methods [1] - The online voting system will be available from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, either via trading terminal or internet platform [2] - Shareholders with multiple accounts can aggregate their voting rights across all accounts [3] - Duplicate votes through different methods will be counted based on the first vote cast [3] Attendance Requirements - Only shareholders registered by the close of business on September 10, 2025, are eligible to attend the meeting [4] - Shareholders must complete registration in advance to ensure smooth proceedings [4] Proxy Voting - Shareholders can appoint a proxy to attend and vote on their behalf, with specific documentation required for both natural and legal persons [4][5] - The proxy must indicate their voting intention on the proxy form [7]

Report Information - Reported Company: Jianzhijia [17] - Industry: Pharmaceutical Commerce [2] - Research Date: August 29, 2025 [17] Core Views - The company is facing difficulties in obtaining medical insurance qualifications for newly opened stores, but is actively communicating with regulatory authorities. It is reducing its reliance on medical insurance and expanding non - medical insurance business, with the medical insurance settlement ratio dropping to 40% in H1 2025, a 4% year - on - year decrease [24]. - Through category adjustment, the company has achieved certain results. The proportion of prescription drug revenue structure decreased by 2.31%, while non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26]. Summary by Directory 01. Research Basic Situation - Research Object: Jianzhijia [17] - Industry: Pharmaceutical Commerce [17] - Reception Time: 2025 - 08 - 29 [17] - Reception Personnel: Chairman and General Manager Lan Bo, Financial Controller and Board Secretary Li Heng, Independent Director Guan Yunhong [17] 02. Detailed Research Institutions - Institutions: Investors and others [20] 03. Research Institution Proportion - No relevant content provided 04. Main Content Data - **Category Structure Change**: Newly opened stores in some areas have difficulties in obtaining medical insurance qualifications. The company is actively communicating with regulatory authorities. In H1 2025, the medical insurance settlement ratio was 40%, a 4% year - on - year decrease. The proportion of prescription drug revenue structure decreased by 2.31%, non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - **Online Business**: The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26].

Market Overview - The Shanghai Composite Index closed at 3857.93 points, above the annual line, with a change of 0.37% [1] - The total trading volume of A-shares reached 28,301.97 billion yuan [1] Stocks Breaking Annual Line - A total of 22 A-shares have surpassed the annual line today, with notable stocks including Guoan Co., Transsion Holdings, and ST Huawen, showing divergence rates of 6.70%, 5.14%, and 4.43% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Changjiang Electric, ST Zhongzhuang, and Laobaigan Liquor [1] Top Divergence Rates - The top three stocks with the highest divergence rates are: - Guoan Co. (10.07% increase, 6.70% divergence) - Transsion Holdings (7.17% increase, 5.14% divergence) - ST Huawen (4.86% increase, 4.43% divergence) [1] Additional Stock Performance - Other notable stocks include: - Shenyang Machine Tool (4.49% increase, 3.75% divergence) - Shangong Shenbei (4.20% increase, 3.64% divergence) - ST Boda (4.10% increase, 3.48% divergence) [1]

Core Insights - The company reported a revenue of 4.457 billion yuan and a net profit of 72.3782 million yuan for the first half of 2025, marking a year-on-year growth of 15.11% [1] Group 1: Business Transformation - The company is shifting its strategy from "meeting customer needs" to "stimulating customer demand" amidst a decline in customer traffic and average transaction value in the pharmaceutical retail industry [1] - The company is reducing its reliance on medical insurance and is deepening its transformation towards health products, specialized services, and omnichannel marketing [1] Group 2: Cost Control and Efficiency - The company has achieved a reduction in operating expenses, with a year-on-year decrease of 0.83% in total expenses for the first half of the year [1] - Continuous control over store rental, promotional, distribution, and management expenses has contributed to reversing the trend of increasing store costs [1]

证券之星消息，8月29日医药商业板块较上一交易日下跌0.12%，润达医疗领跌。当日上证指数报收于 3857.93，上涨0.37%。深证成指报收于12696.15，上涨0.99%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 26.40 | 6.58% | 18.38万 | | 4.79亿 | | 605266 | 健之佳 | 21.31 | 3.05% | 4.19万 | | 8973.71万 | | 000411 | 英特集团 | 11.64 | 2.65% | 18.32万 | | 2.15亿 | | 603716 | 塞力医疗 | 33.95 | 2.57% | 1 50.26万 | | 17.00亿 | | 600833 | 第一医药 | 13.26 | 2.47% | 8.99万 | | 1.19亿 | | 600538 | 国发股份 | 6.47 | 1.41% | 15.80万 | | 1.01亿 | ...

Group 1 - The core viewpoint of the article is that Jianzhijia (SH 605266) held its 12th meeting of the 6th Board of Directors on August 28, 2025, to review the agenda including the 2025 semi-annual report and its summary [1] - For the first half of 2025, Jianzhijia's revenue composition was as follows: 90.17% from pharmaceutical retail and services, 5.51% from other businesses, 4.17% from convenience retail, and 0.15% from pharmaceutical wholesale [1]

Summary of the Conference Call for Jianzhijia Company Overview - **Company**: Jianzhijia - **Period**: First half of 2025 Key Industry Insights - **Revenue Performance**: Jianzhijia experienced a slight revenue decline of 0.64% year-on-year, attributed to challenges in the healthcare policy environment. However, the company managed to achieve a 15% increase in net profit attributable to shareholders through cost control and efficiency improvements [2][5][6]. - **Product Structure Adjustment**: The company reduced the proportion of prescription drugs by 6.67% while increasing sales of OTC drugs by 3.9%. The focus is on enhancing the marketing of brands like Kefu Mei and Fuyi Yan, aiming to boost their sales to tens of millions [2][8]. - **Online Business Growth**: The share of online business increased to 29.6%, with a 13% rise in overall revenue, compensating for some offline losses [2][9]. Core Strategies and Measures - **Cost Control and Efficiency**: Jianzhijia implemented cost control measures starting in 2024, resulting in a significant reduction in expense growth rates. The first quarter saw a 4.74% increase in expenses, down from 13.42% the previous year, and the second quarter further decreased to 6.21% [7]. - **Healthcare Policy Response**: The company is addressing challenges posed by healthcare policies through the establishment of internet hospitals and compliance efforts, advocating for practical policy considerations [2][12]. - **Focus on Health and Beauty Products**: Jianzhijia plans to develop health and beauty products, collaborating with partners like Beitaini to enhance operational efficiency and reduce price competition [2][13]. Financial Performance - **Net Profit Growth**: The net profit attributable to shareholders increased by 15% year-on-year, with a significant 120% year-on-year growth in non-recurring net profit in the second quarter [2][6]. - **Impact of Healthcare Policies**: The company faced a 4% decline in healthcare revenue compared to the previous year, but growth in non-healthcare products helped mitigate this impact [5]. Challenges and Future Outlook - **Store Count Reduction**: Jianzhijia reduced its store count by 82 due to local healthcare policy restrictions, yet managed to achieve some recovery through internal growth strategies [4]. - **Future Goals**: The company aims to continue its cost reduction efforts, having completed about 40% of its annual target, and plans to enhance operational efficiency and inventory management [11][34]. - **Market Potential**: Despite regulatory challenges, the health and beauty sector shows significant growth potential, with a notable increase in sales share for functional skincare products [14]. Technology and Innovation - **AI Utilization**: Jianzhijia is leveraging AI technologies, such as the Deepseek model, for operational diagnostics and efficiency improvements [3][29]. - **O2O Business Model**: The company’s O2O business has been successful due to a solid operational team and refined management practices, ensuring synergy between online and offline sales [2][28]. Regulatory Environment - **Impact of Regulatory Changes**: The company acknowledges the high regulatory burden in the industry, which presents both challenges and opportunities for long-term healthy development [12][19]. - **Future of Small Pharmacies**: The regulatory environment may lead to a consolidation of the market, with smaller pharmacies facing significant challenges in maintaining profitability [20][21]. Conclusion Jianzhijia is navigating a complex regulatory landscape while focusing on cost control, product diversification, and leveraging technology to enhance operational efficiency. The company is optimistic about future growth opportunities in the health and beauty sector despite current challenges.

Group 1 - The company reported a revenue of 4.457 billion yuan for the first half of the year, representing a year-on-year decrease of 0.64% [1] - The net profit attributable to shareholders of the listed company was 72.3782 million yuan, showing a year-on-year increase of 15.11% [1] - The basic earnings per share were 0.47 yuan per share [1]

证券代码：605266 证券简称：健之佳 公告编号：2025-047 健之佳医药连锁集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第一次临时股东会 召开的日期时间：2025 年 9 月 17 日 14 点 30 分 召开地点：云南省昆明市盘龙区联盟街道旗营街 10 号健之佳总部 14 楼会议 室 股东会召开日期：2025年9月17日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号—规范运作》 等有关规定执行。 (七) 涉及公开征集股东投票权 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自202 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-045 健之佳医药连锁集团股份有限公司 第六届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 健之佳医药连锁集团股份有限公司（以下简称"公司"）第六届监事会第九 次会议通知于 2025 年 8 月 23 日以电子邮件方式通知全体监事，会议于 205 年 8 月 28 日上午 10:00 以现场加通讯参会方式在云南省昆明市盘龙区联盟街道旗营 街 10 号健之佳总部十八楼召开，应参加监事 3 人，实际参加监事 3 人，会议由 监事会主席金玉梅女士主持，符合《公司法》及《公司章程》等有关规定。 二、监事会会议审议情况 全体与会监事经认真审议和表决，形成以下决议： （一)、审议《关于公司<2025 年半年度报告>及摘要的议案》 议案表决情况：同意 3 票；反对 0 票；弃权 0 票，此议案获得通过。 1 经审核，监事会认为公司《2025 年半年度报告》的编制和审议程序符合法 律、法规、《公司章程》和公司内部管理制度等各项规定 ...